Amlodipine Besylate Market is predicted to reach USD 0.56 billion at a CAGR of 5.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Amlodipine Besylate Market”.

The Amlodipine Besylate Market is estimated to register a CAGR of 5.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Amlodipine Besylate Market— Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals.

Amlodipine Besylate Market Highlights

The global Amlodipine Besylate Market is accounted to register a CAGR of 5.00% during the forecast period and is estimated to reach USD 0.56 billion by 2032.

The growth of the amlodipine besylate market is fueled by heightened alcohol and tobacco consumption, along with a surge in awareness programs addressing cardiovascular diseases. Additionally, increased investments in cardiovascular departments contribute to this upward trend.

Access Full Report @ https://www.marketresearchfuture.com/reports/amlodipine-besylate-market-22023

Segment Analysis

The global Amlodipine Besylate Market has been segmented based on the Type and Application.

Based on the Type, the market is segmented into 5 mg Tablets and 10 mg Tablets. The 5 mg Tablets segment was attributed to holding the largest market share in 2023. Tablets are the most favored among all medicine forms due to their extremely effective composition and easy-to-consume features. For example, as in the journal of the American Heart Association in January 2022, CADUET is manufactured from a combination of drugs such as atorvastatin, a member of the group of HMG CoA reductase inhibitors with 5 mg amlodipine besylate, a calcium channel blocker that was found to be effective in hypertension and high cholesterol).

Based on the Application, the Amlodipine Besylate Market has been segmented into High Blood Pressure and Heart Diseases. The heart disease segment occupies a majority share of the market due to a growing sedentary lifestyle, inadequate dietary habits, and an increasing number of senior citizens. Furthermore, the occurrence of human genetic disorders has been on the rise globally, which provides another significant basis for this market segment. For instance, the US-based organization American Heart Association, in its 2022 published report, says that the age-adjusted prevalence rate of cardiovascular diseases is 7,345.1 per every 100,000 people in 2020.

Regional Analysis

The global Amlodipine Besylate Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Amlodipine Besylate Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Amlodipine Besylate Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Amlodipine Besylate Market comprises the Middle East, Africa, and Latin America.

The largest market share for the Amlodipine Besylate Market was maintained by the North American regional sector. This is the result of various causes, which relate to the high rate of high blood pressure that is linked to lifestyle factors and the aging population in this region. It is estimated that the number of Americans ages 65 and older will reach 58 million by 2022, and it will become 82 million by 2050 (up from 47%). The older population, in turn, is assumed to grow at 23% by 2050. Older Americans as a population group comprise a larger percentage today than at any other time in U.S. history. Consequently, North America’s progressive healthcare system and the higher accessibility to medical services promote the wide-scale prescription and the use of Amlodipine Besylate.

Moreover, the Europe market has been persistently growing over the forecast period. Europe is experiencing a very high aging rate, which leads to a higher occurrence of chronic illnesses like high blood pressure. The number of patients willing to take medicine to prevent or control disease increases with age, contributing to the overall demand for amlodipine besylate. According to the EU-27 definition of older people (those aged 65 or more), the number of such people will increase dramatically, from the figure of 90.5 mln people in 2019 to the projected figure of 129.8 mln in 2050. This phase involves a huge rise in the number of individuals in the EU-27 aged 75-84 years (56.1 %), while the number of aged 65-74 years is projected to increase by 16.6 %. Contradictorily, the latest forecasts indicate that elderly people less than 55 years old will be 13.5% less numerous in the EU-27 by 2050.

The economic health of several Asia-Pacific countries is marking a positive trend. The amount of people spending on healthcare is also increasing. This will increase the availability of drugs like amlodipine besylate, which would also help the growth of the market. Government expense on health in the budget of the central and state governments in FY23 touched 2.1% of GDP and 2.2% in FY22, as compared to 1.6% in FY21, according to the Economic Survey 2022-23, In the Interim Union budget of the financial year 2024-25, the government provided Rs. ₹ 90,659 crore (US$ 10.93 billion) to the Ministry of Health & Family Welfare (MoHFW).

Furthermore, the rest of the world's Amlodipine Besylate Market is divided into the Middle East, Africa, and Latin America. Because the healthcare sector in these areas is being developed and scientific achievements in the medical field are growing, life expectancy is also rising. As per the UN report, population aging is listed among the major demographic trends that shape Latin America in particular and the Caribbean region in general, and the number of people over 60 years old reached 88.6 million in 2022, with 13.4% of the total population. In 2030, the number is expected to grow to over 16.5% of the total population. In 2050, the share of elderly will comprise as much as 25.1% of the total population (almost 203 million people), which will translate into twice as many older persons as in 2022, with 193 million elderly being expected. As a result, there will be an increase in the elderly having these diseases, which make them vulnerable to cardiovascular diseases such as hypertension that may necessitate more amlodipine besylate medicines.

Key Findings of the Study

• The global Amlodipine Besylate Market is expected to reach USD 0.56 billion by 2032, at a CAGR of 5.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because of the increasing incidence of hypertension.


• Based on Type, the 5 mg Tablets segment was attributed to holding the largest market in 2023.


• Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals are the key market players.